Mixed results for Valeant
Valeant Pharmaceuticals, the parent company of Bausch + Lomb, saw revenues for the third quarter decline by 10 percent from the same quarter in 2016, down to $2,200 million. However, it said that its Bausch + Lomb and International segment achieved a healthy performance, with strong 6 percent organic revenue ...
Already an Eyewear Intelligence subscriber? Sign in here.
Subscribe today
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
- Organisation-wide access across offices, people and devices
To continue reading this article register now.